Needham & Company Starts Cidara Therapeutics (CDTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cidara Therapeutics' (CDTX) CD101 IV Granted FDA Fast-Track Designation
May 11, 2015 8:34 AM EDTCidara Therapeutics (NASDAQ: CDTX) announced that the U.S. Food and Drug Administration (FDA) has designated the companys lead antifungal product candidate, CD101 IV, as a Qualified Infectious Disease Product (QIDP) with Fast Track status. The QIDP and Fast Track designations are for the use of CD101 IV in the treatment of candidemia and invasive candidiasis.
The QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), offers certain incentives for the development of new antibacterial or antifungal drugs, including eligibility for Fast Track, priority review and,... More
Wedbush Starts Cidara Therapeutics (CDTX) at Outperform
May 11, 2015 7:08 AM EDTWedbush initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Outperform rating and a price target of $22.00.
Analyst David Nierengarten commented, "CDTX is addressing the large unmet need for new antifungal agents. Systemic fungal infections are associated with high mortality and an increasingly... More
Jefferies Starts Cidara Therapeutics (CDTX) at Buy
May 11, 2015 6:41 AM EDTJefferies initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Buy rating and a price target of $25.00.
Analyst Eun K. Yang commented, "While early in development, CDTX provides a risk-balanced portfolio: relatively low-risk lead candidate CD101 for serious fungal infections & high-risk/high-reward Cloudbreak immunotherapy for... More
Leerink Partners Starts Cidara Therapeutics (CDTX) at Outperform
May 11, 2015 6:32 AM EDTLeerink Partners initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Outperform rating and a price target of $24.00, saying CD101 has the potential to be a best-in-class anti-fungal agent.
Analyst Paul Matteis commented, "Cidara is a biotechnology company that is focused on developing... More
